|Bid||32.81 x 500|
|Ask||32.86 x 400|
|Day's Range||32.30 - 33.08|
|52 Week Range||27.60 - 56.44|
|PE Ratio (TTM)||420.64|
|Dividend & Yield||1.36 (4.13%)|
|1y Target Est||N/A|
Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.
Yitzhak Peterburg, interim president and CEO of Teva Pharmaceutical, talks about the disruption facing the traditional health care industry.
Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.